GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in immunotherapies and vaccines for cancers and infectious diseases, has announced its participation in two significant investor conferences this September. These events provide an important platform for the company to showcase its progress and engage with the investment community.
David Dodd, Chairman and CEO of GeoVax, will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 7:00 a.m. ET. The conference will take place at the Lotte New York Palace Hotel in New York City. Investors and interested parties can access the presentation via a webcast link. Additionally, senior management from GeoVax will be available for one-on-one meetings with registered attendees during the event.
Later in the month, on September 25, 2024, at 2:55 p.m. ET, Dodd will also present at the virtual Emerging Growth Conference. This presentation will be accessible through a separate webcast link. Both presentations are titled "GeoVax Corporate Update," suggesting that the company will provide comprehensive information about its current operations, research progress, and future plans.
These investor conferences come at a crucial time for GeoVax, as the company is making significant strides in its clinical programs. The company's lead clinical program, GEO-CM04S1, a next-generation COVID-19 vaccine, has recently been awarded a BARDA-funded contract for a 10,000-participant Phase 2b clinical trial. This trial aims to evaluate the efficacy of GEO-CM04S1 against an approved COVID-19 vaccine, potentially positioning GeoVax as a key player in the ongoing fight against the pandemic.
Furthermore, GEO-CM04S1 is currently undergoing three Phase 2 clinical trials, exploring its potential as a primary vaccine for immunocompromised patients, a booster for patients with chronic lymphocytic leukemia (CLL), and a more robust, durable COVID-19 booster for healthy patients who previously received mRNA vaccines. These diverse applications highlight the versatility and potential impact of GeoVax's vaccine technology.
In the oncology field, GeoVax is advancing Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, which is in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. This program underscores the company's commitment to addressing critical unmet needs in cancer treatment.
GeoVax's participation in these investor conferences is particularly noteworthy given the company's strong intellectual property portfolio and experienced leadership team. The presentations offer an opportunity for investors to gain insights into GeoVax's progress across its diverse pipeline and understand the potential value creation in both the infectious disease and oncology spaces.
As the biotechnology sector continues to play a crucial role in addressing global health challenges, GeoVax's updates at these conferences may provide valuable information for investors considering the company's potential impact on vaccine development and cancer therapies. The company's advancements in COVID-19 vaccine research, particularly for vulnerable populations, and its innovative approaches to cancer treatment position it as a company to watch in the coming months.
